Nephrocare consolidated PAT swings to ₹33.5 Cr as finance costs collapse; margin eases
revenue +23.47% · margins expanding
₹303.4 Cr
+23.47% YoY
₹33.53 Cr
10.77%
₹3.34
Nephrocare Health Services (NephroPlus) reported consolidated revenue of ₹303.4 Cr for Q2 FY27, up 23.5% YoY and 7.7% QoQ, ahead of the top end of management's standing 15-20% revenue CAGR guidance reiterated on the FY26 Q4 call. Consolidated PAT swung to a profit of ₹33.5 Cr from a loss of ₹9.5 Cr in the year-ago quarter (Q2 FY26) and was up 4.9% QoQ against ₹32.0 Cr in Q1 FY27; EPS came in at ₹3.34 versus a loss per share of ₹1.12 a year earlier. Standalone (India-only) PAT was ₹14.3 Cr on revenue of ₹176.6 Cr, up a slower 13.3% YoY — the overseas businesses are growing well ahead of the domestic franchise and widening the gap between standalone and consolidated growth rates.
Q2 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
The YoY turnaround is almost entirely a finance-cost story rather than an operating one. Consolidated finance costs fell to ₹3.1 Cr from ₹45.0 Cr a year ago — a collapse consistent with IPO-linked deleveraging: the company used ₹136.0 Cr of its IPO proceeds to prepay borrowings (fully utilised as of this quarter, per its use-of-proceeds disclosure) and paid-up equity capital jumped roughly 5.5x around the December 2025 listing, implying pre-IPO instruments were converted to equity. Strip out finance costs and underlying operating margin actually eased, from about 17.8% of income a year ago and 16.2% last quarter to roughly 15.2% now — other expenses crept up as a share of revenue even as cost-of-materials and employee costs held steady, likely reflecting the cost of the overseas build-out. Growth itself is overseas-led: Philippines revenue rose 36.5% YoY to ₹104.7 Cr and Uzbekistan 39.6% YoY to ₹33.4 Cr, versus India's 10.9% YoY rise to ₹160.9 Cr. The Saudi Arabia joint venture remains a drag, with its share-of-loss widening to ₹3.9 Cr from ₹3.6 Cr last quarter.
The stock went into the print at ₹625, down 3.7% over the past month of trading.
NephroPlus reiterated its commitment to a 15% to 20% revenue CAGR over the next three to four years, driven by a three-pronged growth strategy: existing clinic ramp-up, new clinic rollouts in existing geographies, and expansion into new countries or significant acquisitions/PPP projects. The company plans to maintain a
— This quarter: beat
No Q2-specific street estimates were found (FY27 full-year consensus pegs revenue near ₹1,160 Cr and EPS ₹16.60, per sharpely.in, too broad for a quarterly read), and the company did not issue a results press release with management commentary alongside this filing, so there is no fresh management framing to reconcile against. On the corporate side, the Group signed ten Philippines Asset Transfer Agreements (~₹92.6 Cr) and a Kazakhstan SPA for Dialysis Center Almaty LLP (~₹11.3 Cr) during the quarter, with purchase price allocation still provisional; subsequently, on October 27, 2026, it closed an asset-transfer acquisition of JCM Health Summit Inc. in the Philippines. Separately, a ₹14.79 Cr tax demand against a subsidiary was declared invalid on November 2, 2026, removing a legal overhang. None of this changes the core read: revenue growth is running ahead of guidance and increasingly overseas-driven, but the headline profit turnaround reflects a lighter balance sheet post-IPO rather than improving unit economics, which actually slipped a touch both sequentially and year-on-year.
W1
Core operating margin ex-finance costs: slipped to ~15.2% in Q2 FY27 from ~16.2% in Q1 FY27 and ~17.8% a year ago — watch whether this stabilizes
W2
Integration/contribution of the Philippines ATAs (~₹92.6 Cr), Kazakhstan's Dialysis Center Almaty LLP (~₹11.3 Cr), and the Oct 27, 2026 JCM Health Summit deal, once purchase-price allocation finalizes within 12 months
W3
Whether 23.5% YoY revenue growth holds above the top of the 15-20% CAGR guide, and whether the Saudi JV loss (₹3.9 Cr this quarter) stabilizes
Guided growth held, margin squeeze from geographies—Saudi tender outcome critical
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit Q2 revenue guidance (₹303 Cr). Reaffirmed 15–20% CAGR (no change). Transparent on margin drivers (new geographies, listing costs). PAT growth 35% (adjusted) but reported NPM 10.8% vs adjusted 13% flags one-time impacts.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
NephroPlus delivered Q2 numbers on guidance (₹303 Cr, +23.5% YoY), reaffirmed 15–20% CAGR multi-year target, but compressed EBITDA margin by ~110 bps YoY due to new-geography investment costs (Kazakhstan, Saudi Arabia). Saudi Arabia tender outcome in Feb 2027 is a binary swing; until then, margin recovery is constrained by ramp costs. India platform model is solid but under-utilised at 75%; near-term growth relies on inorganic clinic adds and execution risk in new markets.
₹303.4 Cr
Revenue · +23.5% YoY₹33.5 Cr
Reported PAT · +null% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 revenue 303 Cr, +23.5% YoY
METDelivered 303.4 Cr, matches +23.5% claim
H1 EBITDA margin 23%, adjusted PAT margin 13%
METDelivered NPM 10.8% (reported); adjusted PAT 76.1 Cr / H1 585 Cr = 13% (adjusted)
Margin compression from FY26 to H1 FY27 about 80 bps
METFY26 full-year margin 23.8%, H1 FY27 EBITDA 23%—compressed but in 'healthy range'
India platform model kicks in, margins will recover over time
PartialIndia margin stable, investment costs from new geographies (Kazakhstan, Saudi) depressing group margin YoY
Saudi Arabia Ministry of Health tender, 11,720 patients across 4 clusters
METMinistry tender just released; NephroPlus 1 of 12 qualified global bidders; tender due Feb 2027, binary outcome
Earnings quality
What changed since the last call
International revenue mix grew to 47%
UpgradeH1 FY27 international revenue ~47% of total (up from 42% in FY26), driven by Philippines growth & Saudi/Kazakhstan entry. Price per treatment in international markets ~₹8,200 vs India ~₹2,785.
Saudi Arabia entry announced
New1 clinic in Riyadh operational; home dialysis launched in Riyadh & Jeddah. Ministry tender issued (11,720 patients, 4 clusters); 1 of 12 qualified global providers. Binary outcome in Feb 2027.
Margin guidance maintained despite YoY compression
NeutralEBITDA margin H1 FY27 23% vs FY26 YE 23.8% (~80 bps compression). Management maintains will stay 'healthy' but acknowledged new-geography investment costs; no recovery timeline given.
Clinic net additions slowed
NeutralNet addition of 13 clinics in India (487→500, against 40–50 annual target), attributed to focus on utilization ramp vs greenfield expansion. Philippines +11 in H1; Philippines & India capex allocation shifting to ramp vs new units.
The Q&A
Analysts pushed hard on: (1) margin compression vs international mix (why not higher margins if 47% is higher-priced int'l?), (2) Saudi Arabia binary risk and capex outlays, (3) Philippines competitive intensity & greenfield vs acquisition strategy. Management held firm on 15–20% CAGR guidance, reaffirmed return thresholds, and explained margin as temporary (new-geography investment costs, listing costs, depreciation in Kazakhstan). Tone was patient but confident; no retreat from prior commitments.
Tender eligibility & pricing — Akshay Thakur, Helios Capital
AnsweredQCBS-based tendering now common in India (vs L1 price model). More tenders moving to QCBS, raising NephroPlus win probability. Dialyzer pricing stable, supply increasing, prices remain flat (no major change expected).
Geography selection criteria — Akshay Thakur, Helios Capital
PartialMacro: sustainable network, repatriation of profits possible, political stability, financial unit economics, ability to plug India platform, margin sustainability. Micro: financial feasibility, availability of renal patients in country.
Margin compression explanation — Divyanshi Shah, HUF Capital
AnsweredPrivate company vs listed company transition: new quarterly audits, provisioning (ECL), legal/tax costs. COGS improved 95 bps to 22% of revenue. Professional/hospital fees improved 83 bps. But other expenses (int'l ops, listing, ECL) rose 160 bps. Core operational metrics improving; non-core expansion temporary.
Philippines competitive intensity — Divyanshi Shah, HUF Capital
Partial55 clinics, second-largest network in Philippines. Market fragmented (500+ small clinics). NephroPlus well-positioned. Brand value, no major margin concerns. Competition up but so is patient demand.
Home dialysis market potential — Yug Modi, AB Capital
AnsweredSaudi new tender mentions 10–15% home care mix. Home dialysis margin slightly higher than clinic (capex per patient higher but multi-patient usage). Early stage: ~20 patients on HD in Saudi (home ~10, in-center ~10). Pricing 10–20% premium in developed markets. Very early numbers.
Clinic growth vs existing ramp — Umesh Laddha, Ambit Capital
AnsweredIndia capacity at 75% utilization. Room for organic growth. Net addition 40 clinics; about 80–20 rule: majority growth from clinic additions (capacity building) + organic ramp (utilization). Will continue adding clinics to add capacity, utilization will grow gradually.
Clinic ramp-up stabilization timing — Umesh Laddha, Ambit Capital
AnsweredIndia brownfield (existing, captive): stabilize in 1 month or max. India greenfield: 18–24 months. Philippines greenfield: 3–6 months (already running). PPP contracts: variable, lump-sum contribution. Average India clinic: 10 beds; can vary 5–20.
Saudi Arabia opportunity & timeline — Naman Bagrecha, IIFL Capital
PartialTender due Feb 2027, evaluation 4–6 months after. FY27 capex >₹165 Cr (vs FY26 ₹165 Cr). Saudi in investment phase; cannot assure win. If win, further capex next FY. For now, 1 clinic + home dialysis in pilot. Tender outcome binary.
Capacity utilization & headroom — Naman Bagrecha, IIFL Capital
Answered74% overall. Dialysis doesn't operate 100% (3 shifts, third shift typically less used). Max theoretical ~90%. Room for organic growth; adding clinics also grows capacity.
India clinic adds: PPP vs captive breakdown — Naman Bagrecha, IIFL Capital
PartialPPP contracts lumpy (chunk-based), captive steady (month-on-month). Q2 alone 32 net adds (vs ₹40–50 guidance annual). Clinics can have variability (5–20 beds). Not changing 40–50 guidance; BD activity cycles naturally. Over time, averages out.
Currency impact on revenue & profitability — Nilanjan Karfa, TCG AMC
AnsweredForex contributed ~3% of revenue growth in Q2. Uzbekistan currency (som) appreciated 10% vs rupee. 97% of growth from non-forex factors (organic, inorganic, price). Most pricing-driven from international mix (higher capex, higher RPT).
Price per treatment (RPT) drivers in international markets — Nilanjan Karfa, TCG AMC
AnsweredInternational RPT much higher (₹8,200) vs India (₹2,785). Most of price increase driven by international mix (47% of H1 revenue, up from 42%). Not materially driven by price changes within country; macro pricing stable. Three growth levers: (1) existing clinic ramp, (2) new clinics in existing geographies, (3) new geographies (expansion).
Home services vs clinic services margin profile — Nilanjan Karfa, TCG AMC
AnsweredHome services margin slightly higher operationally; higher capex deployment per patient (capex per bed shared vs single patient). Return profile similar across both in 3–4 year horizon. Market penetration 10–20% in developed markets; early stage in Saudi.
Saudi Arabia home dialysis licenses — Nilanjan Karfa, TCG AMC
AnsweredSaudi clinic in Riyadh = conventional clinic license + home license (both held by NephroPlus). Not PPP; operational. Saudi tender primarily is PPP/government tender model with binary outcome.
NIDA (Nurse Academy) impact on margins — Devang Patel, Sameeksha Capital
PartialNIDA is for global supply (nurses). Early stage: 100–200 nurses planned. Not a significant needle mover for margins currently. Cost addition modest; upside if it solves nurse shortage globally and synergizes at international level.
Philippines market dynamics & competition — Harsh Shah, Avener Capital
AnsweredTwo large players in Philippines: Diaverum (world 3rd-largest, 30+ countries) + local player (15 years, already operating). NephroPlus second-largest (55 clinics, 30+ cities). Market fragmented with 500+ small operators. Competition up; patient demand also growing.
Dialyzer pricing trends long-term — Harsh Shah, Avener Capital
AnsweredPrice hike ~decade ago. Now flat. Supply increasing (new producers in India starting production). Pricing likely to remain stable or have minor decreases (from PVC impact). No major inflation-linked hikes expected.
Pharmacy products margin cap — Devang Patel, Sameeksha Capital
AnsweredPharma products <1% of NephroPlus revenue. Margin capping applies to hospital pharma (cancer meds, etc.), not dialysis-related. Minimal impact on dialysis line.
Outsourcing adoption (BD opportunity) — Anubhav Mukherjee, Prescient Capital
AnsweredOrganized market share ~20% but growing. Hospital-level dynamics: smaller hospitals (80-bed) or nursing homes often don't see P&L at dialysis dept level. They resist outsourcing. Cultural change needed. Expected slow evolution, not sudden inflection. 5-year horizon: expect 20% → 30% organized (slow, evolutionary).
Return thresholds & capital allocation — Anubhav Mukherjee, Prescient Capital
AnsweredEvery project must hit return thresholds. We grow disciplined. Lower return thresholds, we'll add 30–40 more clinics yearly. But point of growing is generating healthy margins and returns, not at-any-cost. Growth + healthy returns is the mantra.
Guidance
Revenue CAGR 15–20% over 3–4 years (reaffirmed)
HighManagement reaffirmed prior multi-year guidance from FY26 call. No change. Contingent on Saudi Arabia tender, clinic ramp success, Philippines consolidation, and India organic growth.
EBITDA margin to remain in 'healthy range' (23%+ implied)
MediumH1 margin 23% vs FY26 YE 23.8%. Management expects margins to stabilize/recover as new geographies mature (Kazakhstan ramp, Saudi post-tender). No specific annual target given.
Adjusted PAT margin at 13% (H1 FY27), expanded 107 bps YoY
LowH1 adjusted, not guidance. Management noted margin compression temporary; investment phase costs (listing, ECL, new geographies). Recovery timeline not specified.
FY27 capex >₹165 Cr (vs FY26 ₹165 Cr, i.e., increase expected)
MediumIncrease reflects Saudi tender capex, Kazakhstan ramp, India clinic capacity additions. H1 ₹102 Cr deployed; FY27 >₹165 Cr suggests acceleration H2.
Risks the call surfaced
Saudi Arabia tender
HighMinistry of Health tender: NephroPlus 1 of 12 global bidders for 11,720 patients across 4 clusters. Win/loss outcome directly impacts capex deployment (₹15–20 Cr+), international growth momentum, and FY27–FY28 revenue trajectory.
Margin compression in new geographies
MediumH1 EBITDA margin 23% vs FY26 23.8% (80 bps compression). Management cites Kazakhstan ramp, Saudi investment, listing costs, ECL provisioning. If ramp-up slower than expected (Kazakhstan stabilization 18+ months, Saudi post-tender capex), margins could remain pressured longer.
Philippines competition & pricing
MediumPhilippines 55 clinics, 2nd-largest network but facing competition from Diaverum (global #3, 30+ countries) and fragmented local base (500+ small clinics). Recent price hikes (10 years ago) now stabilized. If competition escalates or market consolidation shifts share, pricing power could erode.
India market penetration slowness
MediumIndia dialysis market ~20% organized vs 80% fragmented (small operators, hospital in-house units). Hospitals (esp. smaller, 80-bed) don't track P&L by department; resist outsourcing due to control/preferential treatment concerns. Management expects 20% → 30% organized in 5 years. If adoption remains slow, India growth constrained to organic clinic additions + existing ramp.
Nurse supply constraint
LowAccess to trained renal nurses is a constraint on international expansion. NephroPlus launched NIDA (Nephroplus International Dialysis Academy) to train nurses from Philippines & India for global deployment. Early-stage (100–200 nurses target); if supply doesn't materialize, Saudi Arabia and international ramp could face staffing bottleneck.
Management
Score 7/10. Clear on strategy (3 growth levers: existing clinic ramp, new clinics in existing geographies, new country expansion). Transparent on cost drivers (listing, ECL, new-geography investment). But cautious on specifics (Saudi tender, clinic bed counts, capex by region). Hit Q2 revenue guidance (₹303 Cr, +23.5% YoY). Reaffirmed 15–20% CAGR multi-year guidance. Delivered on clinic additions (570 total, 6 countries). Margin compression acknowledged but attributed to temporary investment costs, not operational failure.
1 · Feb 2027
Saudi Arabia Ministry of Health tender decision (1 of 12 bidders, 11,720 patients)
2 · Next 12m
Kazakhstan Almaty clinic ramp-up and market validation in new geography
3 · Next 2-3 qtrs
Philippines 55-clinic platform consolidation; greenfield strategy shift vs acquisition
India platform model is solid but under-utilised at 75%; near-term growth relies on inorganic clinic adds and execution risk in new markets.
Growth held, but margin squeeze and Saudi binary await
NephroPlus delivered 23.5% revenue growth and reaffirmed 15–20% CAGR guidance—but Q2 profit leans on adjustments not fully itemized. The real story is margin compression in new geographies and a February 2027 tender that could swing ₹15+ Crore of capex.
₹303.4 Cr
+23.5% YoY, on guidance
₹33.5 Cr
NPM 10.8%
₹76.1 Cr
13% margin, +35% YoY
23%
vs 23.8% FY26; −80 bps YoY
NephroPlus posted a textbook guidance hit: Q2 revenue ₹303.4 Cr aligned with +23.5% growth flagged on the call, and management reaffirmed the 15–20% multi-year CAGR without change. But beneath the surface, the quarter is a study in timing: reported profit ₹33.5 Cr masks a richer underlying run (adjusted PAT ₹76.1 Cr H1, +35% YoY), margin compressed by 80 basis points despite a higher-priced international mix now at 47% of revenue, and the company's most important catalyst—a Saudi Arabia Ministry of Health tender—flips to a decision in February 2027. The stock has digested this: down 20.6% from its all-time high, FII positions trimming. The question is whether the margin squeeze is temporary (investment phase, listing costs) or structural.
Where the margin went
The 80 basis point margin compression—from FY26 YE's 23.8% to H1 FY27's 23%—is the quarter's most scrutinized line. On paper, it shouldn't exist: international revenue jumped to 47% of the mix (up from 42%), commanding ₹8,200 per treatment versus India's ₹2,785. Higher price per unit should widen margin. It didn't, and analysts pressed hard.
Despite improving international mix, why hasn't margin expanded? What's driving the 80 bps compression?
Management's answer: private-to-listed transition. Quarterly audits, ECL provisioning (new regulatory requirement), legal and tax due diligence, listing-related costs. But there's more. COGS improved 95 basis points to 22% of revenue; professional fees dropped 83 bps. The offset came from elsewhere: "other expenses" rose 160 bps—driven by new-geography rollouts (Kazakhstan Almaty clinics ramping, Saudi Arabia home dialysis & clinic in Riyadh, capex in both pre-revenue or early-ramp), forex headwinds (Uzbek som appreciated 10% vs rupee, a tailwind, but Egypt and other emerging-market ops absorbed currency volatility), and ECL provisioning. Core operations are intact; the margin hit is investment-phase and regulatory.
Q2 revenue ₹303 Cr, +23.5% YoY
Delivered ₹303.4 Cr; +23.5% YoY confirmed
Supported
15–20% CAGR guidance maintained over 3–4 years
Reaffirmed on the call; no change from prior year
Supported
H1 EBITDA margin 23%, adjusted PAT margin 13%
H1 EBITDA ₹134 Cr / ₹585 Cr rev = 23% ✓; Adjusted PAT ₹76.1 Cr / ₹585 Cr = 13% ✓
Supported
Margin compression ~80 bps is temporary; will recover as new geographies mature
Compression confirmed (FY26 YE 23.8% → H1 FY27 23%). Recovery timeline and magnitude not specified.
Partial; transparency gap
India clinic platform at 75% utilization with room to grow
500 clinics, 75% utilization, target 40–50 annual net adds. Room exists, but Q2 net adds only 13 (vs 40–50 run rate)
Partial; execution questions
Saudi Arabia Ministry tender: 1 of 12 qualified global bidders, 11,720 patients
Tender released. NephroPlus holds 1 clinic + home dialysis in Saudi (pilot validation). Tender decision Feb 2027.
Supported; binary outcome pending
What changed on this call
International revenue mix jumped to 47% of total (up from 42% FY26). RPT ₹8,200 vs India ₹2,785. Validates diversification strategy but reveals why margin hasn't expanded (investment capex, ramp costs in Saudi & Kazakhstan offset higher prices).
Saudi Arabia Ministry of Health tender formally released (11,720 patients, 4 clusters, 12 global bidders). NephroPlus 1 of 12. Decision Feb 2027. Binary outcome: if won, ₹15–20+ Cr capex swing; if lost, capex scales back dramatically.
Kazakhstan Almaty acquisition (2 clinics) now in ramp phase; management guided 18–24 months to stabilization. Early-stage loss provision contributing to adjusted/reported gap.
NIDA (Nurse Academy) launched to solve global renal nurse shortage. Early-stage (100–200 nurses target). Strategic for international rollout but not a near-term margin driver.
India clinic net adds slowed to 13 in Q2 (vs 40–50 annual target), attributed to focus on ramp (75% utilization) over greenfield expansion. PPP contracts (Haryana, Tamil Nadu, Bihar) steady, but capex allocation shifting.
Philippines grew +11 clinics H1 (total 55); second-largest market. But competition intensifying (Diaverum global #3 entering, local fragmentation = 500+ small players). Pricing power stable but under watch.
The bull-bear ledger
Revenue growth 23.5% YoY sustained; 15–20% CAGR reaffirmed over 3–4 years without retreat. Guidance hit is rare in a listed transition.
Adjusted PAT H1 +35% YoY (₹76.1 Cr); organic profit momentum strong despite margin compression. Core operations healthy.
India platform solid: 500 clinics, 33,000+ guests, 75% utilization, room for organic ramp. Largest market, most predictable cash generator.
International diversification working: 47% of revenue now from higher-priced geographies (Philippines 55 clinics, Uzbekistan stable, Saudi/Kazakhstan entry). RPT 3x India.
Reported PAT ₹33.5 Cr leans on adjustments not granularly itemized (~₹42.6 Cr gap for H1 flagged as Saudi JV loss, forex, ECL, listing costs). Earnings quality concern; investor transparency gap.
EBITDA margin compressed 80 bps YoY despite higher-priced mix; recovery timeline vague. If ramp-up slower than guided (Kazakhstan 18+ months, Saudi post-tender), margin could stay pressured into FY28.
Saudi Arabia tender is binary (win/loss). ~50% implied odds (not quantified); Feb 2027 decision. Loss would derail capex plans and international momentum. Win uncertain enough that management said 'by no means can assure you.'
India outsourcing adoption slow (20% organized market vs 80% fragmented). Management expects 20% → 30% over 5 years—evolutionary, not inflectional. Limits near-term clinic rollout acceleration.
Philippines competition from Diaverum (global #3) and local fragmentation (500+ small players). Pricing power stable but market share defense required.
Nurse supply constraint structural globally; NIDA early-stage solution. If nurse pipeline doesn't materialize, Saudi & Kazakhstan ramp could face staffing bottleneck.
Risks, ranked by how much they should concern a holder
Saudi Arabia tender binary outcome (Feb 2027 decision pending)
HighNephroPlus is 1 of 12 global bidders for 11,720 patients. Win probability ~50% (implicit; not quantified by management). Loss derails ₹15–20+ Cr capex deployment and international growth optionality. Win upside would validate Saudi as a material revenue/margin contributor by FY28+.
Margin recovery timeline vague; new-geography ramp-up could extend pressure
HighH1 margin 23% vs FY26 YE 23.8% (80 bps compression). Management called it 'temporary investment phase' but gave no recovery timeline. Kazakhstan stabilization 18+ months, Saudi post-tender timing unknown, listing costs ongoing. If margin stays at 23% through FY27–FY28, at-risk profile for valuation multiple (especially if EPS growth stalls).
Adjusted vs reported profit gap (₹42.6 Cr H1) not granularly itemized; opacity on one-time items
MediumQ2 reported PAT ₹33.5 Cr (NPM 10.8%) vs underlying business run rate suggests large adjustments. Management cited Saudi JV loss, forex, ECL, listing costs but didn't quantify each line. Investors left inferring the gap; risk of earnings surprise if one-time items recur or were underestimated.
India clinic net adds slowed (13 in Q2 vs 40–50 annual target); refocus on ramp over expansion
MediumManagement attributed to utilization ramp priority (75% target still underused) vs greenfield expansion. But if PPP contract sequencing slows or capex allocation to international competes harder, India organic growth could lag near term. 40–50 guidance holds, but quarterly lumpiness may persist.
Philippines competition intensity rising; Diaverum (global #3) + 500+ local fragmented players
MediumNephroPlus 55 clinics (second-largest in Philippines). Diaverum has 30+ countries, global scale, pricing power. Local competitors 500+ small. Dialyzer pricing flat (stable input cost), but if competition escalates, clinic margins & market share could erode. NephroPlus brand established but not immune.
India outsourcing adoption structural bottleneck; slow 5-year pace (20% → 30%)
MediumOrganized dialysis market ~20% in India. Fragmented base 80% (small operators, hospital in-house units). Hospitals resist outsourcing (control, department P&L opacity). Management expects 5-year evolution to 30% organized. If adoption remains slower or stalls, clinic rollout acceleration limited; India growth capped to organic clinic adds + ramp.
Nurse supply constraint globally; NIDA early-stage and unproven
Low–MediumRenal nurse shortage is real (management flagged as 'constraint on international expansion'). NIDA targets 100–200 nurses from Philippines/India for global deployment. Early-stage; if supply pipeline doesn't materialize, Saudi & Kazakhstan ramp could face staffing bottleneck and cost inflation.
How the street is reading this
The stock sits at ₹620.55 (as of Nov 12, 2026), down 20.6% from its all-time high of ₹781.4 and trading between its 52-week lows and above its 200-day average (₹623.28). RSI is neutral at 46.9, and volume is normal. The drawdown likely reflects two forces: listed-company overhead (quarterly audits, listing costs), margin compression (investors initially hoping 47% international mix would expand EBITDA, but ramp capex and ECL offset the price upside), and Saudi binary uncertainty (until Feb 2027 clarity, capex plans are contingent).
FII positioning has weakened: FII holdings fell from 9.94% (FY26 Q4) to 8.78% (FY27 Q1)—a trim of 116 basis points. DII held steady (+40 bps). Promoter stake unchanged at 63.85%. The FII outflow suggests foreign money is waiting for Saudi clarity or margin stabilization before re-entering.
Block/bulk deals show mixed signals: Polar Capital Healthcare Opportunities Fund accumulated ₹25.45 Crore at ₹705.00 (large strategic buy), but Edoras Investment Holdings PTE LTD (a Singapore vehicle, likely promoter-linked or strategic partner) sold ₹8.42 Crore twice at ₹710.45 and ₹710.18 (near the highs). Mansi Share & Stock Broking showed mixed activity (bought ₹8.23 Cr @ ₹705.24, sold ₹8.16 Cr @ ₹710.45). The pattern suggests profit-taking near ₹710 and value accumulation around ₹705. Institutional buyers (Polar Capital) stepping in at depressed levels is a mild positive signal; foreign exit (Edoras) near highs is cautionary.
Overall street read: Hold, not sell. The margin compression and Saudi binary are real, but the company hit guidance, reaffirmed CAGR, and delivered 35% adjusted PAT growth. The stock has repriced from the high, making it less frothy. Foreign money waiting; domestic buying on the dip suggests some confidence in medium-term rebound (post-Saudi clarity, margin stabilization).
The debate
1 · Saudi Arabia Ministry tender decision (Feb 2027)
Binary outcome. Win = ₹15–20+ Cr capex deployment, FY28 revenue acceleration, Saudi as material center of gravity by FY29. Loss = capex scaled, international growth optionality curtailed. This is the single most important event for FY27–FY28 re-rating.
2 · Margin stabilization path (FY27 H2 + FY28)
Watch for EBITDA margin recovery from 23% toward 24%+ as new-geography capex-to-revenue ratios normalize (Kazakhstan breakeven, Saudi post-tender ramp, listing costs amortize). If margins stay at 23% through FY28, growth story loses momentum. If they recover to 24%+ by FY28, growth + margin expansion narrative re-emerges.
3 · India clinic utilization & net adds trajectory
India remains the cash engine (75% utilization). Monitor quarterly clinic net adds (target 40–50 annually). If adds accelerate back to 20/quarter and utilization moves toward 80%+, India organic growth is on track. If adds stay lumpy (13 in Q2) and utilization plateaus, clinic rollout might be self-limiting (capex competing with international).
4 · Adjusted vs reported PAT reconciliation
Investors should ask management for a granular breakdown of the ~₹42.6 Cr H1 adjustment gap (Saudi JV loss, forex, ECL, listing costs, each quantified separately). Lack of clarity here is a credibility drain. Expect clarification by Q3 FY27 or annual report filing.
5 · Philippines competitive positioning & clinic economics
NephroPlus is second-largest (55 clinics) but facing Diaverum (global #3) and 500+ fragmented locals. Monitor clinic-level economics (margin, utilization) and market share trends. If pricing power erodes or clinic adds slow, Philippines story weakens.
The bottom line
NephroPlus delivered a steady quarter: revenue growth 23.5% on guidance, 15–20% CAGR reaffirmed, adjusted PAT +35% YoY. But steady is not exciting, and the quarter is defined by what's not expanding—margins, despite a higher-priced international mix at 47% of revenue. The margin hit is explained (investment capex, listing costs, ECL) but recovery is contingent and timeline vague. The stock has repriced down 20.6% from highs, and foreign money is trimming (FII -116 bps), but selective buyers (Polar Capital) are accumulating at ₹705 levels, suggesting some conviction in the medium term.
The real story is February 2027: Saudi Arabia Ministry of Health tender decision. Win, and capex/growth optionality unlocks for FY28+. Lose, and the company grinds at 15–20% organic growth in a margin-compressed state—less exciting. Until Saudi clarity, the stock likely oscillates between ₹600–650. Holders should be comfortable waiting; the fundamentals are intact, but re-rating is contingent on margin stabilization + Saudi outcome, both 2–3 quarters away.
The single number to track: EBITDA margin in FY27 H2 and FY28. If it recovers to 24%+ by FY28 Q2, the growth + margin expansion narrative re-emerges and the stock re-rates. If it stays at 23%, growth story is capped and multiple likely compresses.